If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Merck (MRK).

Rakovina Therapeutics is leveraging AI to accelerate the discovery of drug candidates for the treatment of cancer.

This useful study by Gao et al identifies Hspa2 as a heterogeneous transcript in the early embryo and proposes a plausible mechanism showing interactions with Carm1. The authors propose that ...

Merck is the 15th largest multinational in Ireland by employment, according to the IDA ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

A health communications partnership has been launched today by UK strategic comms agency Lexington Communications and US ...

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

If unorthodoxy and discipline could be blended and bottled, Bob Duggan would have another multibillion-dollar product. For ...

By prioritising the circular economy, healthcare and pharmaceutical industries can become leaders in sustainability, ensuring their resilience and long-term success in a world where sustainable practi ...

Heart valve replacement involves removing the diseased heart valve. Newer techniques go through the groin. Learn how open ...